1-3 of 3
Juan Jose Perez-Ruixo
Close
Sort by
Journal Articles

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Xu Steven Xu, Xiaoyu Yan, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Peter M. Voorhees, MD, Kevin Liu, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Juan Jose Perez Ruixo, Honghui Zhou, Pamela L Clemens
Journal: Blood
Blood (2015) 126 (23): 4254.
https://doi.org/10.1182/blood.V126.23.4254.4254
Published: 2015
Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu
Journal: Blood
Blood (2015) 126 (23): 4222.
https://doi.org/10.1182/blood.V126.23.4222.4222
Published: 2015
Journal Articles

Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS)

John Harrold, Philippe Jacqmin, Per Olsson, Isabelle Delor, Phuong Khanh Morrow, MD, Bing-Bing Yang, PhD, Andrew Chow, Juan Jose Perez-Ruixo
Journal: Blood
Blood (2014) 124 (21): 690.
https://doi.org/10.1182/blood.V124.21.690.690
Published: 2014